BACKGROUND & AIMS: In polycystic liver diseases, cyst formation involves cholangiocyte hyperproliferation. In polycystic kidney (PCK) rats, an animal model of autosomal-recessive polycystic kidney disease (ARPKD), decreased intracellular calcium [Ca(2+)](i) in cholangiocytes is associated with hyperproliferation. We recently showed transient receptor potential vanilloid 4 (Trpv4), a calcium-entry channel, is expressed in normal cholangiocytes and its activation leads to [Ca(2+)](i) increase. Thus, we hypothesized that pharmacologic activation of Trpv4 might reverse the hyperproliferative phenotype of PCK cholangiocytes. METHODS: Trpv4 expression was examined in liver of normal and PCK rats, normal human beings, and patients with autosomal-dominant polycystic kidney disease or ARPKD. Trpv4 activation effect on cell proliferation and cyst formation was assessed in cholangiocytes derived from normal and PCK rats. The in vivo effects of Trpv4 activation on kidney and liver cysts was analyzed in PCK rats. RESULTS: Trpv4 was overexpressed both at messenger RNA (8-fold) and protein (3-fold) levels in PCK cholangiocytes. Confocal and immunogold electron microscopy supported Trpv4 overexpression in the livers of PCK rats and ARPKD or autosomal-dominant polycystic kidney disease patients. Trpv4 activation in PCK cholangiocytes increased [Ca(2+)](i) by 30%, inhibiting cell proliferation by approximately 25%-50% and cyst growth in 3-dimensional culture (3-fold). Trpv4-small interfering RNA silencing blocked effects of Trpv4 activators by 70%. Trpv4 activation was associated with Akt phosphorylation and beta-Raf and Erk1/2 inhibition. In vivo, Trpv4 activation induced a significant decrease in renal cystic area and a nonsignificant decrease in liver cysts. CONCLUSIONS: Taken together, our in vitro and in vivo data suggest that increasing intracellular calcium by Trpv4 activation may represent a potential therapeutic approach in PKD. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: In polycystic liver diseases, cyst formation involves cholangiocyte hyperproliferation. In polycystic kidney (PCK) rats, an animal model of autosomal-recessive polycystic kidney disease (ARPKD), decreased intracellular calcium [Ca(2+)](i) in cholangiocytes is associated with hyperproliferation. We recently showed transient receptor potential vanilloid 4 (Trpv4), a calcium-entry channel, is expressed in normal cholangiocytes and its activation leads to [Ca(2+)](i) increase. Thus, we hypothesized that pharmacologic activation of Trpv4 might reverse the hyperproliferative phenotype of PCK cholangiocytes. METHODS:Trpv4 expression was examined in liver of normal and PCKrats, normal human beings, and patients with autosomal-dominant polycystic kidney disease or ARPKD. Trpv4 activation effect on cell proliferation and cyst formation was assessed in cholangiocytes derived from normal and PCKrats. The in vivo effects of Trpv4 activation on kidney and liver cysts was analyzed in PCKrats. RESULTS:Trpv4 was overexpressed both at messenger RNA (8-fold) and protein (3-fold) levels in PCK cholangiocytes. Confocal and immunogold electron microscopy supported Trpv4 overexpression in the livers of PCKrats and ARPKD or autosomal-dominant polycystic kidney diseasepatients. Trpv4 activation in PCK cholangiocytes increased [Ca(2+)](i) by 30%, inhibiting cell proliferation by approximately 25%-50% and cyst growth in 3-dimensional culture (3-fold). Trpv4-small interfering RNA silencing blocked effects of Trpv4 activators by 70%. Trpv4 activation was associated with Akt phosphorylation and beta-Raf and Erk1/2 inhibition. In vivo, Trpv4 activation induced a significant decrease in renal cystic area and a nonsignificant decrease in liver cysts. CONCLUSIONS: Taken together, our in vitro and in vivo data suggest that increasing intracellular calcium by Trpv4 activation may represent a potential therapeutic approach in PKD. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Melissa A Muff; Tatyana V Masyuk; Angela J Stroope; Bing Q Huang; Patrick L Splinter; Seung-Ok Lee; Nicholas F Larusso Journal: Lab Invest Date: 2006-06-19 Impact factor: 5.662
Authors: Sertac N Kip; Larry W Hunter; Qun Ren; Peter C Harris; Stefan Somlo; Vicente E Torres; Gary C Sieck; Qi Qian Journal: Circ Res Date: 2005-03-24 Impact factor: 17.367
Authors: Tatyana V Masyuk; Anatoliy I Masyuk; Vicente E Torres; Peter C Harris; Nicholas F Larusso Journal: Gastroenterology Date: 2006-12-20 Impact factor: 22.682
Authors: Stephanie J Leuenroth; Dayne Okuhara; Joseph D Shotwell; Glen S Markowitz; Zhiheng Yu; Stefan Somlo; Craig M Crews Journal: Proc Natl Acad Sci U S A Date: 2007-03-06 Impact factor: 11.205
Authors: Magdalena Adeva; Mounif El-Youssef; Sandro Rossetti; Patrick S Kamath; Vickie Kubly; Mark B Consugar; Dawn M Milliner; Bernard F King; Vicente E Torres; Peter C Harris Journal: Medicine (Baltimore) Date: 2006-01 Impact factor: 1.889
Authors: Michelle N Sullivan; Michael Francis; Natalie L Pitts; Mark S Taylor; Scott Earley Journal: Mol Pharmacol Date: 2012-06-11 Impact factor: 4.436
Authors: Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres Journal: Nat Rev Nephrol Date: 2015-04-14 Impact factor: 28.314
Authors: James H Tabibian; Anatoliy I Masyuk; Tetyana V Masyuk; Steven P O'Hara; Nicholas F LaRusso Journal: Compr Physiol Date: 2013-01 Impact factor: 9.090
Authors: Mykola Mamenko; Oleg L Zaika; Nabila Boukelmoune; Jonathan Berrout; Roger G O'Neil; Oleh Pochynyuk Journal: J Biol Chem Date: 2013-05-24 Impact factor: 5.157
Authors: Sergio A Gradilone; Stefan Habringer; Tatyana V Masyuk; Brynn N Howard; Anatoliy I Masyuk; Nicholas F Larusso Journal: Am J Pathol Date: 2014-01-13 Impact factor: 4.307